跳至主要内容
临床试验/NCT00215176
NCT00215176已完成2 期

A Study of Modafinil for Atypical Depression

Duke University0 个研究点目标入组 65 人开始时间: 2003年2月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
65
主要终点
HAM-D-29 (Hamilton Depression 29-Item Scale, with Atypical Features)

研究概览

简要总结

The purposes of the study are to: 1) evaluate the short-term efficacy and safety of modafinil in atypical depression; and 2) to evaluate the efficacy of modafinil in preventing relapse of atypical depression. The hypothesis is that modafinil is safe and effective in the treatment of atypical depression.

详细描述

This study on the safety and efficacy of modafinil on atypical depression has an initial 12-week open label treatment period with modafinil that is followed by a 12-week double-blind, randomized parallel treatment period with either modafinil or matching placebo. Patients who demonstrate at least minimal improvement after 12 weeks are randomly assigned to either continuing treatment at their current dose or switched to matching placebo for 12 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adults 18-65 years of age
  • DSM-IV criteria for major depressive episode with atypical features as assessed by the Atypical Depression Diagnostic Scale
  • minimum score of 18 on the Hamilton Depression Scale (29-item version) at baseline
  • baseline Clinical Global Impressions Severity score of 4 or more
  • written informed consent
  • negative serum pregnancy test for women of childbearing potential

排除标准

  • any current primary DSM-IV Axis I disorder other than depression
  • history of DSM-IV diagnosis of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition
  • history of substance abuse or dependence within the last 3 months
  • suicide risk or serious suicide attempt with the last year
  • clinically significant medical condition or laboratory or EKG abnormality
  • history of non-response to three prior adequate trials of antidepressants
  • women of childbearing potential who are unwilling to practice an acceptable method of contraception
  • history of hypersensitivity to modafinil
  • use of an investigational medication within the last 28 days
  • use of antidepressant medication with 28 days of screening

结局指标

主要结局

HAM-D-29 (Hamilton Depression 29-Item Scale, with Atypical Features)

次要结局

  • SOS (Severity of Symptoms Scale)
  • BFI (Brief Fatigue Inventory)
  • ADDS (Atypical Depression Diagnostic Scale)
  • CGI-S (Clinical Global Impressions Severity Scale)
  • CGI-I (Clinical Global Impressions Improvement Scale)
  • SCL-90 (Symptom Checklist 90)
  • ESS (Epworth Sleepiness Scale)
  • FSS (Fatigue Severity Scale)

研究者

发起方
Duke University
申办方类型
Other

相似试验